1. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial). Issue 3 (18th September 2015) Authors: Stahler, A.; Heinemann, V.; Giessen‐Jung, C.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling‐Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; von Einem, J.C.; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A.; Modest, D.P. Journal: International journal of cancer Issue: Volume 138:Issue 3(2016:Feb. 01) Page Start: 739 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 519POutcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC). (18th September 2017) Authors: Rivera Herrero, F.; Bachet, J-B.; Modest, D.P.; de Braud, F.; Pietrantonio, F.; Koukakis, R.; Demonty, G.; Douillard, J-Y. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?. (March 2017) Authors: Modest, D.P.; Neumann, U.P.; Pratschke, J. Journal: European journal of cancer Issue: Volume 73(2017) Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). (January 2019) Authors: Holch, J.W.; Ricard, I.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D.P.; Westphalen, C.B.; von Einem, J.C.; Michl, M.; Heinemann, V. Journal: European journal of cancer Issue: Volume 106(2019) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer—central evaluation of FIRE-3. (January 2018) Authors: Modest, D.P.; Denecke, T.; Pratschke, J.; Ricard, I.; Lang, H.; Bemelmans, M.; Becker, T.; Rentsch, M.; Seehofer, D.; Bruns, C.J.; Gebauer, B.; Modest, H.I.; Held, S.; Folprecht, G.; Heinemann, V.; Neumann, U.P. Journal: European journal of cancer Issue: Volume 88(2018) Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). (October 2017) Authors: Modest, D.P.; Ricard, I.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Westphalen, C.B.; Holch, J.W.; von Einem, J.C.; Held, S.; Heinemann, V. Journal: European journal of cancer Issue: Volume 84(2017) Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Treatment sequencing in metastatic colorectal cancer. (March 2019) Authors: Modest, D.P.; Pant, S.; Sartore-Bianchi, A. Journal: European journal of cancer Issue: Volume 109(2019) Page Start: 70 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗